Plastic Prefilled Syringes: A Better Fit for Autoinjector Systems - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Plastic Prefilled Syringes: A Better Fit for Autoinjector Systems
The authors describe the ways in which plastic prefilled syringes can be an alternative that provides consistent performance, protects drugs prone to degradation, and enhances patient safety.

Pharmaceutical Technology


Despite the fact that glass is still the predominant material, plastic prefilled syringes are gaining ground because of the many benefits associated with cyclic olefin polymer resins. Drug manufacturers that seek autoinjector technology for their products, particularly for biologicals and vaccines, should consult a vendor that understands primary container performance. Syringes' dimensions should be as consistent as possible, and the syringes should preferably be molded instead of formed, to help overcome the problem of break-force variability. Plastic syringes also can improve the safety of the delivery by eliminating tungsten or glue contamination. If a glass syringe is necessary, the autoinjector itself can be modified to aid the delivery process by registering the force on the strongest part of the syringe. This technique helps to overcome the dimensional variability of the glass prefilled syringe, reduce breakage, provide a consistent depth of injection, and create a reliable system that delivers the dose easily and effectively to the patient.

Douglas Stout* is director of strategic market development, and Vinod Vilivalam is director of strategic market and technical development for the Daikyo Crystal Zenith prefillable and vial platform, both at West, 101 Gordon Dr., Lionville, PA 19341, tel. 732.946.2929, fax 732.945.2189.

*To whom all correspondence should be addressed.


1. M.N. Eakins, Am. Pharm. Rev. 10 (6), 47–51 (2007).

2. B. Harrison and M. Rios, Pharm. Technol. 31 (3), 50–60 (2007).

3. B. Detournay et al., Eur. Hosp. Pharm. 4 (4), 109–113 (1998).

4. M.J. Akers et al., PDA J. Pharm. Sci. Technol. 61 (5), 337–361 (2007).

5. B. Eu et al., poster presented at AAPS National Biotechnology Conference, Toronto, June 2008.

6. MHRA, Class 2 Drug Alert, Medicines Recall, Reference MDR 03-10/06, Neulasta SureClick Injection Device (London, Oct. 4, 2006).

7. R. Esfandairy et al., poster presented at AAPS National Biotechnology Conference, Toronto, June 2008.

8. B. Lahendro,, (2008), accessed Oct. 19, 2009.

9. J. Shin et al., Pure Appl. Chem. 77 (5), 801–814 (2005).

10. M.N. Eakins, Bioprocess Int. 3 (6), 52–58 (2005).

11. J.S. Bee et al., J. Pharm. Sci. 98 (9), 3290–3301 (2009).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here